Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry

Marco Losa, Paolo Beck-Peccoz, Gianluca Aimaretti, Carolina Di Somma, Maria Rosaria Ambrosio, Diego Ferone, Antonella Giampietro, Salvatore M. Corsello, Maurizio Poggi, Carla Scaroni, Nan Jia, Gilberto Mossetto, Salvatore Cannavò, Vincenzo Rochira

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective To determine whether characteristics and outcomes of Italian patients in the observational global Hypopituitary Control and Complication Study (HypoCCS) differed according to the degree of GH deficiency (GHD). Design Patients were grouped by tertiles of stimulated GH peak concentration at baseline (Group A lowest tertile, n = 342; Group B middle tertile, n = 345; Group C highest tertile, n = 338). Results Baseline demographics, lipid levels, body mass index categories and mean Framingham cardiovascular risk indexes were similar in the three groups and remained substantially unchanged over time, with no subsequent significant between-group differences (except mean levels of triglycerides increased in the highest tertile group). GHD was adult-onset for >75% of patients in all groups. The percentage of patients with multiple pituitary deficiencies was higher in Group A than in the other groups; isolated GHD was reported with highest frequency in Group C. Patients in Group A received the lowest mean starting dose of GH. Hyperlipidaemia at baseline was reported in 35·1%, 31·1% and 24·7% of patients in groups A, B and C, respectively (P = 0·029). Mean duration of GH treatment was 7·21, 5·45 and 4·96 years, respectively. The proportion of patients with adverse events did not differ significantly between groups, with a low prevalence over time of diabetes and cancer. Conclusions In Italian patients from HypoCCS, the level of GH deficit did not influence changes over time in metabolic parameters or adverse event profile, despite differences in GHD severity at baseline and in the starting GH dose.

Original languageEnglish
Pages (from-to)527-535
Number of pages9
JournalClinical Endocrinology
Volume83
Issue number4
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Growth Hormone
Pituitary Dwarfism
Hyperlipidemias
Triglycerides
Body Mass Index
Demography
Lipids
Neoplasms

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry. / Losa, Marco; Beck-Peccoz, Paolo; Aimaretti, Gianluca; Di Somma, Carolina; Ambrosio, Maria Rosaria; Ferone, Diego; Giampietro, Antonella; Corsello, Salvatore M.; Poggi, Maurizio; Scaroni, Carla; Jia, Nan; Mossetto, Gilberto; Cannavò, Salvatore; Rochira, Vincenzo.

In: Clinical Endocrinology, Vol. 83, No. 4, 01.10.2015, p. 527-535.

Research output: Contribution to journalArticle

Losa, Marco ; Beck-Peccoz, Paolo ; Aimaretti, Gianluca ; Di Somma, Carolina ; Ambrosio, Maria Rosaria ; Ferone, Diego ; Giampietro, Antonella ; Corsello, Salvatore M. ; Poggi, Maurizio ; Scaroni, Carla ; Jia, Nan ; Mossetto, Gilberto ; Cannavò, Salvatore ; Rochira, Vincenzo. / Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry. In: Clinical Endocrinology. 2015 ; Vol. 83, No. 4. pp. 527-535.
@article{d66a708835cf4e3393925168dbc5b396,
title = "Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry",
abstract = "Objective To determine whether characteristics and outcomes of Italian patients in the observational global Hypopituitary Control and Complication Study (HypoCCS) differed according to the degree of GH deficiency (GHD). Design Patients were grouped by tertiles of stimulated GH peak concentration at baseline (Group A lowest tertile, n = 342; Group B middle tertile, n = 345; Group C highest tertile, n = 338). Results Baseline demographics, lipid levels, body mass index categories and mean Framingham cardiovascular risk indexes were similar in the three groups and remained substantially unchanged over time, with no subsequent significant between-group differences (except mean levels of triglycerides increased in the highest tertile group). GHD was adult-onset for >75{\%} of patients in all groups. The percentage of patients with multiple pituitary deficiencies was higher in Group A than in the other groups; isolated GHD was reported with highest frequency in Group C. Patients in Group A received the lowest mean starting dose of GH. Hyperlipidaemia at baseline was reported in 35·1{\%}, 31·1{\%} and 24·7{\%} of patients in groups A, B and C, respectively (P = 0·029). Mean duration of GH treatment was 7·21, 5·45 and 4·96 years, respectively. The proportion of patients with adverse events did not differ significantly between groups, with a low prevalence over time of diabetes and cancer. Conclusions In Italian patients from HypoCCS, the level of GH deficit did not influence changes over time in metabolic parameters or adverse event profile, despite differences in GHD severity at baseline and in the starting GH dose.",
author = "Marco Losa and Paolo Beck-Peccoz and Gianluca Aimaretti and {Di Somma}, Carolina and Ambrosio, {Maria Rosaria} and Diego Ferone and Antonella Giampietro and Corsello, {Salvatore M.} and Maurizio Poggi and Carla Scaroni and Nan Jia and Gilberto Mossetto and Salvatore Cannav{\`o} and Vincenzo Rochira",
year = "2015",
month = "10",
day = "1",
doi = "10.1111/cen.12839",
language = "English",
volume = "83",
pages = "527--535",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry

AU - Losa, Marco

AU - Beck-Peccoz, Paolo

AU - Aimaretti, Gianluca

AU - Di Somma, Carolina

AU - Ambrosio, Maria Rosaria

AU - Ferone, Diego

AU - Giampietro, Antonella

AU - Corsello, Salvatore M.

AU - Poggi, Maurizio

AU - Scaroni, Carla

AU - Jia, Nan

AU - Mossetto, Gilberto

AU - Cannavò, Salvatore

AU - Rochira, Vincenzo

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objective To determine whether characteristics and outcomes of Italian patients in the observational global Hypopituitary Control and Complication Study (HypoCCS) differed according to the degree of GH deficiency (GHD). Design Patients were grouped by tertiles of stimulated GH peak concentration at baseline (Group A lowest tertile, n = 342; Group B middle tertile, n = 345; Group C highest tertile, n = 338). Results Baseline demographics, lipid levels, body mass index categories and mean Framingham cardiovascular risk indexes were similar in the three groups and remained substantially unchanged over time, with no subsequent significant between-group differences (except mean levels of triglycerides increased in the highest tertile group). GHD was adult-onset for >75% of patients in all groups. The percentage of patients with multiple pituitary deficiencies was higher in Group A than in the other groups; isolated GHD was reported with highest frequency in Group C. Patients in Group A received the lowest mean starting dose of GH. Hyperlipidaemia at baseline was reported in 35·1%, 31·1% and 24·7% of patients in groups A, B and C, respectively (P = 0·029). Mean duration of GH treatment was 7·21, 5·45 and 4·96 years, respectively. The proportion of patients with adverse events did not differ significantly between groups, with a low prevalence over time of diabetes and cancer. Conclusions In Italian patients from HypoCCS, the level of GH deficit did not influence changes over time in metabolic parameters or adverse event profile, despite differences in GHD severity at baseline and in the starting GH dose.

AB - Objective To determine whether characteristics and outcomes of Italian patients in the observational global Hypopituitary Control and Complication Study (HypoCCS) differed according to the degree of GH deficiency (GHD). Design Patients were grouped by tertiles of stimulated GH peak concentration at baseline (Group A lowest tertile, n = 342; Group B middle tertile, n = 345; Group C highest tertile, n = 338). Results Baseline demographics, lipid levels, body mass index categories and mean Framingham cardiovascular risk indexes were similar in the three groups and remained substantially unchanged over time, with no subsequent significant between-group differences (except mean levels of triglycerides increased in the highest tertile group). GHD was adult-onset for >75% of patients in all groups. The percentage of patients with multiple pituitary deficiencies was higher in Group A than in the other groups; isolated GHD was reported with highest frequency in Group C. Patients in Group A received the lowest mean starting dose of GH. Hyperlipidaemia at baseline was reported in 35·1%, 31·1% and 24·7% of patients in groups A, B and C, respectively (P = 0·029). Mean duration of GH treatment was 7·21, 5·45 and 4·96 years, respectively. The proportion of patients with adverse events did not differ significantly between groups, with a low prevalence over time of diabetes and cancer. Conclusions In Italian patients from HypoCCS, the level of GH deficit did not influence changes over time in metabolic parameters or adverse event profile, despite differences in GHD severity at baseline and in the starting GH dose.

UR - http://www.scopus.com/inward/record.url?scp=84941940454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941940454&partnerID=8YFLogxK

U2 - 10.1111/cen.12839

DO - 10.1111/cen.12839

M3 - Article

C2 - 26119712

AN - SCOPUS:84941940454

VL - 83

SP - 527

EP - 535

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 4

ER -